Study in Health Affairs Could Reignite Debate Over Some 340B Hospitals Charity Care

Researchers at The Johns Hopkins University found that nonprofit hospitals spend significantly less on charity care than government or for-profit hospitals.

A study published online by Health Affairs yesterday on nonprofit hospitals’ provision of charity care could renew drug manufacturers’ calls for more control over those hospitals’ participation in the 340B program.

Professors and scientists at The Johns Hopkins University used

Read More »

AHA Warns MedPAC its Recommendations Would Harm 340B Hospitals

Hospitals say that Medicare Part B drug reimbursement changes that MedPAC endorsed last week would amplify the effect of Part B drug payment cuts for 340B hospitals in place since 2018. | Shutterstock

Congressional Medicare policy advisers on Friday unanimously endorsed Medicare Part B drug reimbursement changes that hospitals say would amplify the effect of Part B drug payment cuts for 340B hospitals in place since 2018.

The Medicare Payment Advisory Commission (MedPAC)

Read More »

HHS’s Latest Regulatory Agenda Is Silent on 340B, but Program Rulemaking Is Possible

HHS's latest semi-annual regulatory agenda is mum on 340B, but that doesn't mean there is nothing 340B-related in the pipeline. | Shutterstock

The U.S. Health and Human Services Department (HHS) yesterday released the spring edition of its twice-annual public inventory of forthcoming regulatory actions. Although it was silent about the 340B program, 340B stakeholders shouldn’t breathe a sigh of relief yet.

Just

Read More »

AHA Asks Becerra to Waive a 340B Hospital Eligibility Requirement During COVID-19 Emergency

HHS Secretary Xavier Becerra told a House committee today "We are on this one" in reference to drug companies denying 340B pricing on their products.

The American Hospital Association (AHA) yesterday asked U.S. Health and Human Services (HHS) Secretary Xavier Becerra to temporarily waive 340B program eligibility criteria for hospitals at risk of losing their 340B eligibility due to changes in payer mix caused by

Read More »

For-Profit Hospitals Back Medicare’s 340B Hospital Cuts in Legal Brief, Study, and Blog

The Federation of American Hospitals, led by its President and CEO Chip Kahn, is making its strongest effort to date to preserve Medicare drug reimbursement cuts for 340B hospitals.

The association for U.S. for-profit hospitals yesterday made its strongest pitch yet to preserve the nearly 30 percent cut in what Medicare pays many public and private nonprofit hospitals for physician-administered, 340B-purchased drugs.

The Federation of American Hospitals (FAH) submitted

Read More »

Breaking News

For-Profit Hospitals Make Major Pitch for Keeping Medicare’s 340B Hospital Cuts

United Therapeutics says that, starting May 13, entities must upload their 340B contract pharmacy claims data to its vendor 340B ESP twice monthly to "be eligible to place Bill To / Ship To replenishment orders for United Therapeutics products dispensed through a contract pharmacy.”

The association for U.S. for-profit hospitals submitted a brief to the U.S. Supreme Court and released a study today arguing against reversing the nearly 30 percent cut in what Medicare pays many public and private nonprofit hospitals for physician-administered, 340B-purchased

Read More »

Feds Oppose Hospitals’ Intervention in Three More Pharma 340B Lawsuits

The federal government has asked three more federal judges to not let hospital groups intervene in drug manufacturers' lawsuits challenging HHS's 340B contract pharmacy requirements. | Shutterstock

The federal government has asked federal district judges in Indianapolis, Delaware, and New Jersey to deny hospital groups’ requests for active roles in drug manufacturers Eli Lilly’s, AstraZeneca’s, and Sanofi’s lawsuits against the government over its 340B contract pharmacy requirements.

Read More »

Q2 340B Registration Period Starts April 1

A screen capture from HRSA's user guide for providers wishing to register to participate in the 340B program.

The second of four opportunities this year for covered entities to register themselves, their sites, and their contract pharmacies in the 340B program starts this Thursday, April 1 and ends on Thursday, April 15. New registrants can begin buying discounted

Read More »

Origin Biosciences Posts Limited Distribution Notice on 340B Program Site

The maker of Nulibry, a new, first-of-its-kind drug whose supply is limited, notified providers about how they can buy it at its 340B price.

The manufacturer of Nulibry, a recently approved, first-of-its-kind injectable treatment for a very rare, often fatal genetic disorder that typically appears soon after birth, has posted details about the limited distribution network for the drug on the U.S.

Read More »

HRSA Takes Step Forward on 340B Dispute Resolution Petitions

HRSA this week notified 340B covered entities that it had finished reviewing their administrative dispute resolution petitions for completeness, and determined that they were complete. | Shutterstock

The federal government on Tuesday declared 340B administrative dispute resolution (ADR) petitions by covered entities against drug manufacturers AstraZeneca, Eli Lilly, and Sanofi to be “complete,” a sign that claims against two of the three companies—AstraZeneca and Sanofi—are ready for

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live